m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01213)
Name
DCC-2036
Synonyms
REBASTINIB; DCC-2036; 1020172-07-9; DCC-2036 (Rebastinib); DCC 2036; CHEBI:62166; UNII-75017Q6I97; Rebastinib(DCC-2036); 4-(4-(3-(3-(tert-butyl)-1-(quinolin-6-yl)-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; DCC2036; DP-1919; 4-[4-({[3-Tert-Butyl-1-(Quinolin-6-Yl)-1h-Pyrazol-5-Yl]carbamoyl}amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide; 75017Q6I97; 4-[4-[(5-Tert-butyl-2-quinolin-6-ylpyrazol-3-yl)carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,4-methylbenzenesulfonic acid;4-[4-[(
    Click to Show/Hide
Status
Phase 1/2
Structure
Formula
C30H28FN7O3
InChI
1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40)
InChIKey
WVXNSAVVKYZVOE-UHFFFAOYSA-N
PubChem CID
25066467
TTD Drug ID
D0E0NM
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Angiopoietin 1 receptor (TEK)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Angiopoietin 1 receptor (TEK) is a therapeutic target for DCC-2036. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of DCC-2036 through regulating the expression of Angiopoietin 1 receptor (TEK). [1], [2]
References
Ref 1 Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis. Front Cell Dev Biol. 2021 Feb 18;9:627706. doi: 10.3389/fcell.2021.627706. eCollection 2021.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)